Bispecific diabodies for cancer therapy.
Arndt
Michaela
M
National Cancer Institute at Frederick, Frederick, MD, USA.
Krauss
Jürgen
J
D000818:Animals; D018033:Antibodies, Bispecific / Q000096:biosynthesis* / Q000302:isolation & purification; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D017931:DNA Primers / Q000737:chemistry; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007128:Immunoglobulin Fragments / Q000276:immunology; D007135:Immunoglobulin Variable Region / Q000235:genetics / Q000276:immunology; D017730:Ki-1 Antigen / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism; D008214:Lymphocytes / Q000276:immunology; D008223:Lymphoma / Q000276:immunology / Q000628:therapy; D051379:Mice; D016513:Mice, SCID; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D016133:Polymerase Chain Reaction / Q000379:methods*; D011485:Protein Binding; D017452:Receptors, IgG / Q000276:immunology*; D014183:Transplantation, Heterologous
D018033:Antibodies, Bispecific; D000912:Antibodies, Neoplasm; D017931:DNA Primers; D007128:Immunoglobulin Fragments; D007135:Immunoglobulin Variable Region; D017730:Ki-1 Antigen; D017452:Receptors, IgG